Forest Laboratories Price Target Increased to $77.00 by Analysts at Argus (FRX)
Equities research analysts at Argus raised their target price on shares of Forest Laboratories (NYSE:FRX) from $62.00 to $77.00 in a research note issued to investors on Tuesday, AnalystRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Argus’ price objective suggests a potential upside of 13.69% from the company’s current price.
A number of other firms have also recently commented on FRX. Analysts at UBS AG raised their price target on shares of Forest Laboratories from $57.00 to $72.00 in a research note to investors on Thursday, January 9th. They now have a “neutral” rating on the stock. Separately, analysts at CRT Capital raised their price target on shares of Forest Laboratories from $63.00 to $78.00 in a research note to investors on Thursday, January 9th. They now have a “buy” rating on the stock. Finally, analysts at Buckingham Research upgraded shares of Forest Laboratories from a “neutral” rating to a “buy” rating in a research note to investors on Thursday, January 9th. Seven equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $57.47.
Forest Laboratories, Inc (NYSE:FRX) develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician’s prescription.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.